Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMANOL: Olaparib Maintenance in mCRPC
NCT03434158Phase 2Completed
- Sponsor
- SOGUG
- Start
- Feb 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOGUG. Started Feb 2018; status: completed.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03434158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434158.